EMA: Quality, preclinical and clinical aspects of gene therapy medicinal products – Scientific guideline

EMA Guideline on the quality, non-clinical and clinical aspects of gene therapy medicinal products (GTMPs) (EMA/CAT/80183/2014) sets EU expectations across the full lifecycle for GTMPs under the ATMP framework. It integrates quality/C MC, non-clinical, and clinical principles to support Marketing Authorization Applications (and informs earlier development/IMPDs). Emphasis is on a risk-based, product-specific approach covering identity, strength/content, purity/impurities, potency, safety, and long-term risk management.

• Applies to GTMPs as defined in EU legislation, including viral/non-viral vectors administered in vivo and ex vivo–modified cells where the therapeutic effect is mediated by the recombinant nucleic acid (otherwise, such products may fall under other ATMP categories).

• Excludes prophylactic vaccines against infectious diseases.

• Structured around three pillars:

Quality Aspects

• Design/Genetic construct: Justify vector choice; describe all genetic elements and their functions.

• Starting materials & banks: Control/characterise plasmids, producer cell lines, viral seeds; establish cell-bank/seed-lot systems.

• Manufacturing & controls (GMP): Defined process with CPPs/CQAs, in-process controls, impurities removal; environmental/aseptic controls; container-closure and transport/handling.

• Specifications: Identity; strength/content (e.g., vg/mL, IU, cells/dose/viability); purity/impurities (e.g., empty/full ratio, aggregates; host-cell DNA/protein; residual reagents); adventitious agents including replication-competent viruses, such as RCL (retrovirus), RCR (lentivirus), RCA (adenovirus), or rcAAV (AAV).

• Potency: Quantitative, mechanism-relevant assay(s); matrices/bridging allowed as products/processes evolve.

• Stability & comparability: Protocol and acceptance criteria (real-time/accelerated, in-use, shipping); comparability after changes; reference standards lifecycle.

Non-Clinical Aspects

• Pharmacology/Proof-of-concept: Demonstrate biological activity relevant to the claimed mechanism.

• Biodistribution & persistence: Evaluate tissue distribution, duration of expression, shedding and potential germline exposure.

• Toxicology: Risk-based; include repeat-dose where appropriate; assess insertional mutagenesis/tumorigenicity for integrating vectors; immune responses and re-administration feasibility.

• Environmental risk assessment (GMO): Required for products containing/consisting of GMOs per EU legislation.

Clinical Aspects

• Traditional ADME principles are not applicable; instead, biodistribution, persistence, shedding, and transgene expression are assessed to characterize in vivo behavior.

• Efficacy: Robust study design; randomized controlled trials where feasible; alternative designs acceptable for small/rare populations with strong justification.

• Safety & risk management: Characterize immunogenicity and off-target risks; contraception/ pregnancy considerations where relevant; risk-based long-term follow-up (often required for integrating or long-persisting vectors) integrated into the RMP.